Life360, Inc. — Director's Dealing 2025

Aug 19, 2025

SEC Form 4

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) See Instruction 10.

==> picture [677 x 356] intentionally omitted <==

----- Start of picture text -----

1. Name and Address of Reporting Person [] 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Life360, Inc. [ LIF ]
Synge James X Director 10% Owner
(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Officer (give title below) Other (specify below)
08/15/2025
C/O LIFE360, INC.
4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)
1900 SOUTH NORFOLK STREET, SUITE 310
X Form filed by One Reporting Person
(Street)
Form filed by More than One Reporting Person
SAN MATEO CA 94403
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 3. 4. Securities Acquired (A) or Disposed Of (D) 5. Amount of Securities 6. 7. Nature of Indirect
Date Execution Date, Transaction (Instr. 3, 4 and 5) Beneficially Owned Ownership Beneficial Ownership
(Month/Day/Year) if any Code Following Reported Form: (Instr. 4)
(Month/Day/Year) (Instr. 8) Transaction(s) Direct (D)
(Instr. 3 and 4) or Indirect
Code V Amount (A) or Price (I) (Instr. 4)
(D)
S $ 84.23 (3)
Common stock 08/15/2025 24,919 (2) D 219,835 (5) (6) D
(1) (4)
Common stock 08/15/2025 S 81 (2) D $ 85.25 (4) 219,754 (5) (6) D
(1)
S $ 85.80 (7)
Common stock 08/18/2025 25,000 (2) D 194,754 (5) (6) D
(1) (8)
Held by ICCA Labs,
Common stock 3,966 I
LLC (9)
----- End of picture text -----*

==> picture [677 x 121] intentionally omitted <==

----- Start of picture text -----

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative 2. Convers 3. Transaction 3A. Deemed 4. 5. Number of 6. Date 7. Title and Amount of 8. Price 9. Number 10. Owne 11. Nature
Security (Instr. 3) ion or Date Execution Date, Transaction Derivative Exercisable and Securities Underlying of Deriva of derivative rship of Indirect
Exercise (Month/Day/Year) if any Code Securities Expiration Date Derivative Security tive Securities Form: Beneficial
Price of (Month/Day/Year) (Instr. 8) Acquired (A) (Month/Day/Year) (Instr. 3 and 4) Security Beneficially Direct Ownership
Derivative or Disposed (Instr. 5) Owned (D) or (Instr. 4)
Security of (D) (Instr. Following Indirect (
3, 4 and 5) Reported I) (Instr.
Transaction 4)
Date Ex Expira Amount or (s) (Instr. 4)
ercisabl tion Number of
Code V (A) (D) e Date Title Shares
----- End of picture text -----

Explanation of Responses:

1. The sale being reported on this Form 4 is the sale of Chess Depositary Interests ("CDIs") as converted on a 1:3 common stock to CDI ratio. The CDIs were traded on the Australian Securities Exchange (the "ASX") and were held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX.

2. Reflects the number of common stock equivalent shares underlying the CDIs sold on the ASX.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.91 to $84.85, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3.

4. Reflects the weighted average sale price of the CDIs sold, as converted to USD by multiplying the amount by 3, based on the 3:1 conversion ratio for CDIs to common stock, and then multiplying by the exchange rate of 0.6505 in effect at the time of the sale as published by the Reserve Bank of Australia.

5. Includes the number of common stock underlying CDIs as converted on a 1:3 common stock to CDI ratio. The CDIs are traded on the ASX and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX.

6. Includes 2,810 restricted stock units previously granted, each of which represents a contingent right to receive one share of the Issuer's common stock upon vesting.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.36 to $86.22, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 7.

8. Reflects the weighted average sale price of the CDIs sold, as converted to USD by multiplying the amount by 3, based on the 3:1 conversion ratio for CDIs to common stock, and then multiplying by the exchange rate of 0.652 in effect at the time of the sale as published by the Reserve Bank of Australia.

9. The Reporting Person has shared investment control over Carthona Capital FS Pty Ltd. ("Carthona Capital"). Carthona Capital is a member of ICCA Labs, LLC, an entity that holds an aggregate of 8,219 shares of the Issuer's common stock. The number of shares held as reported herein represents Carthona Capital's proportionate ownership interest in ICCA Labs, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Remarks:

/s/ Jay Sood, as Attorney-in-Fact 08/19/2025 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

• If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.